These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8235706)

  • 21. NCCN Practice Guidelines for Chronic Myelogenous Leukemia.
    Berman E; Clift RA; Copelan EA; Emanuel PD; Erba HP; Glenn MJ; Greenberg PL; Jones RJ; O'Brien S; Saba HI; Schilder R; Snyder DS; Soiffer RJ; Tallman MS; Wetzler M; Ravandi-Kashani F; Kantarjian H; Talpaz M;
    Oncology (Williston Park); 2000 Nov; 14(11A):229-40. PubMed ID: 11195415
    [No Abstract]   [Full Text] [Related]  

  • 22. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K; Tabayashi T; Yamada K; Takeuchi M
    Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia.
    Champlin R
    Exp Hematol; 1995 Oct; 23(11):1148-51. PubMed ID: 7556522
    [No Abstract]   [Full Text] [Related]  

  • 24. [Initial treatment of chronic myelogenous leukemia--interferon or bone marrow transplantation].
    Urabe A
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1381-6. PubMed ID: 10500523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
    Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolated extramedullary relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Au WY; Chan AC; Lie AK; So JC; Liang R; Kwong YL
    Bone Marrow Transplant; 1998 Jul; 22(1):99-102. PubMed ID: 9678803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
    Giralt S; O'Brien S; Talpaz M; Van Besien K; Chan KW; Rondón G; Andersson B; Mehra R; Khouri I; Estey E
    Cytokines Mol Ther; 1995 Jun; 1(2):115-22. PubMed ID: 9384668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on therapy for chronic myelogenous leukemia.
    Weinberger BB
    J La State Med Soc; 1994 Aug; 146(8):341-3. PubMed ID: 7930864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Interferon-alpha therapy in chronic myelogenous leukemia].
    Ohnishi K
    Rinsho Ketsueki; 2000 Apr; 41(4):275-9. PubMed ID: 10846454
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
    Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
    Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
    Tomás JF; Peñarrubia MJ; García JA; Figuera A; Gómez-García de Soria V; Steegmann JL; Arranz R; Cámara R; Gabriel R; Vázquez L
    Med Clin (Barc); 1995 Nov; 105(16):605-11. PubMed ID: 8523939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Interferon alpha in the treatment of chronic myeloid leukemia. Promises, realities, and perspectives].
    Steegmann JL; Granados E; Rodríguez-Salvanés F; Casado LF; Giraldo P; Lavilla E; Gómez-Casares MT; Fernández-Contreras E; Odriozola J
    Sangre (Barc); 1998 Apr; 43(2):137-46. PubMed ID: 9656775
    [No Abstract]   [Full Text] [Related]  

  • 34. Phimosis as a manifestation of chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Kami M; Kanda Y; Sasaki M; Takeda N; Tanaka Y; Saito T; Ogawa S; Honda H; Chiba S; Mitani K; Hirai H; Yazaki Y
    Bone Marrow Transplant; 1998 Apr; 21(7):721-3. PubMed ID: 9578313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laryngeal stenosis associated with chronic graft-versus-host disease following unrelated bone marrow transplantation.
    Hirokawa M; Kume M; Wu T; Ishikawa K; Sawada KI
    Bone Marrow Transplant; 2006 Sep; 38(5):387-8. PubMed ID: 16862163
    [No Abstract]   [Full Text] [Related]  

  • 38. Allogeneic peripheral blood and bone marrow stem cell transplantation for chronic myelogenous leukemia: single center study from Iran.
    Ghavamzadeh A; Iravani M; Jabehdar-Maralani P; Hajrasouliha A; Tavakoli S
    Haematologica; 2003 Apr; 88(4):ELT13. PubMed ID: 12681990
    [No Abstract]   [Full Text] [Related]  

  • 39. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unexpected late graft failure 9 months after HLA-identical bone marrow transplant (BMT) for chronic myeloid leukemia (CML): treatment with a second BMT.
    Gil-Fernández JJ; Arranz R; Cámara R; Alegre A; Figuera A; Fernández-Rañada JM
    Haematologica; 1998 Mar; 83(3):285-7. PubMed ID: 9580418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.